Ratios

		vs industry	vs history
P/E(ttm)	12.00	WCRX's P/E(ttm) is ranked higher than 91% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 29.76 vs. WCRX: 12.00 )	WCRX' s 10-Year P/E(ttm) Range Min: 6.93   Max: 229.44 Current: 12 6.93 229.44
P/S	1.96	WCRX's P/S is ranked higher than 71% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.32 vs. WCRX: 1.96 )	WCRX' s 10-Year P/S Range Min: 1.1   Max: 6.18 Current: 1.96 1.1 6.18
PFCF	6.51	WCRX's PFCF is ranked higher than 95% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 25.89 vs. WCRX: 6.51 )	WCRX' s 10-Year PFCF Range Min: 3.14   Max: 27.1 Current: 6.51 3.14 27.1
EV-to-EBIT	11.26	WCRX's EV-to-EBIT is ranked higher than 78% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 21.70 vs. WCRX: 11.26 )	WCRX' s 10-Year EV-to-EBIT Range Min: 8.6   Max: 2307 Current: 11.26 8.6 2307
PEG	0.33	WCRX's PEG is ranked lower than 67% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.23 vs. WCRX: 0.33 )	WCRX' s 10-Year PEG Range Min: 0.17   Max: 2.44 Current: 0.33 0.17 2.44
Shiller P/E	19.88	WCRX's Shiller P/E is ranked higher than 95% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 30.12 vs. WCRX: 19.88 )	WCRX' s 10-Year Shiller P/E Range Min: 12.74   Max: 83.64 Current: 19.88 12.74 83.64

Dividend & Buy Back

		vs industry	vs history
Dividend Yield	1.30	WCRX's Dividend Yield is ranked higher than 83% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.36 vs. WCRX: 1.30 )	WCRX' s 10-Year Dividend Yield Range Min: 1.3   Max: 2.25 Current: 1.3 1.3 2.25
Dividend Payout	0.2	WCRX's Dividend Payout is ranked lower than 73% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.86 vs. WCRX: 0.2 )	WCRX' s 10-Year Dividend Payout Range Min: 0.16   Max: 0.16 Current: 0.2
Yield on cost (5-Year)	1.30	WCRX's Yield on cost (5-Year) is ranked higher than 82% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.42 vs. WCRX: 1.30 )	WCRX' s 10-Year Yield on cost (5-Year) Range Min: 1.39   Max: 2.25 Current: 1.3 1.39 2.25
Share Buyback Rate	0.1	WCRX's Share Buyback Rate is ranked higher than 84% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -2.00 vs. WCRX: 0.1 )	WCRX' s 10-Year Share Buyback Rate Range Min: 0   Max: -29.7 Current: 0.1

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	26	WCRX's Price/Net Current Asset Value is ranked higher than 77% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.20 vs. WCRX: 26 )	WCRX' s 10-Year Price/Net Current Asset Value Range Min: 15.9   Max: 61.1 Current: 26 15.9 61.1
Price/DCF (Projected)	0.6	WCRX's Price/DCF (Projected) is ranked higher than 69% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.60 vs. WCRX: 0.6 )	WCRX' s 10-Year Price/DCF (Projected) Range Min: 0.4   Max: 1 Current: 0.6 0.4 1
Price/Median PS Value	0.6	WCRX's Price/Median PS Value is ranked higher than 64% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.70 vs. WCRX: 0.6 )	WCRX' s 10-Year Price/Median PS Value Range Min: 0.4   Max: 1.8 Current: 0.6 0.4 1.8
Price/Peter Lynch Fair Value	0.5	WCRX's Price/Peter Lynch Fair Value is ranked higher than 79% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.60 vs. WCRX: 0.5 )	WCRX' s 10-Year Price/Peter Lynch Fair Value Range Min: 0.3   Max: 0.9 Current: 0.5 0.3 0.9
Earnings Yield (Greenblatt)	8.90	WCRX's Earnings Yield (Greenblatt) is ranked higher than 82% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.90 vs. WCRX: 8.90 )	WCRX' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.1   Max: 11.6 Current: 8.9 0.1 11.6
Forward Rate of Return (Yacktman)	47.56	WCRX's Forward Rate of Return (Yacktman) is ranked higher than 98% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.82 vs. WCRX: 47.56 )	WCRX' s 10-Year Forward Rate of Return (Yacktman) Range Min: 18.4   Max: 59.6 Current: 47.56 18.4 59.6

Business Description

Warner Chilcott Limited was formed through a series of acquisitions and divestitures. It began commercial operations on January 5, 2005 when it acquired Warner Chilcott PLC ("Predecessor"). Its Predecessor was incorporated in 1968 as a sales and marketing organization focused on branded pharmaceutical products in Northern Ireland, but in September 2000 expanded into the U.S. pharmaceuticals market through the acquisition of a U.S. pharmaceutical business that marketed a portfolio of products including OVCON and ESTRACE Cream. It is a global pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacture and promotion of its products. It markets and sells the following principal products: Gastroenterology, Women's Healthcare, Dermatology and Urology. The Company employs marketing techniques to identify and target physicians with the highest potential to prescribe its products. In connection with its marketing initiatives, it seeks to efficiently size, deploy, direct and compensate its sales forces in order to grow its market share, sustain product sales growth, revitalize acquired products and successfully launch new products. The pharmaceutical industry is competitive. Protecting its intellectual property, such as trademarks and patents, is a key part of its strategy. The Company relies on patents, trade secrets and proprietary knowledge to protect its products. Its branded products compete with brands marketed by other pharmaceutical companies including large, fully integrated concerns with financial, marketing, legal and product development resources greater than theirs. The U.S. pharmaceutical industry is subject to regulation by national, regional, state and local agencies.
Company Website

Industry:	Drug Manufacturers - Specialty & Generic
Compare:	TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:	G3LA.Germany

Personalized Checklist